

Electronic Acknowledgement Receipt

EFS ID:	9403175
Application Number:	10534348
International Application Number:	
Confirmation Number:	4929
Title of Invention:	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
First Named Inventor/Applicant Name:	Karen Silence
Customer Number:	23628
Filer:	Erik J. Spek/Eileen Flaherty
Filer Authorized By:	Erik J. Spek
Attorney Docket Number:	A0848.70005US00
Receipt Date:	08-FEB-2011
Filing Date:	09-MAY-2005
Time Stamp:	19:26:39
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Reiter_et_al_NatBiotechnol_1996_v14_p1239.pdf	1536056 94ef5a078ac2ae29271e4f026e5593834a2177095a	no	7

Warnings:

Information:

2	NPL Documents	Reiter_et_al_JMolBiol_1999_v2_90_p685.pdf	332392 53c245b4d1346d1a3eb1396b13e131a5c0b4f	no	14
Warnings:					
Information:					
3	NPL Documents	Rheinnecker_et_al_JImmunol_1996_v157_p2989.pdf	1006138 4b2ce749341a6f5ca3b45395e4997a0a2f514c0319	no	9
Warnings:					
Information:					
4	NPL Documents	Riechmann_et_al_JImmunol_Meth_1999_v231_p25.pdf	1158522 59bcb9e1137ba7617387555905e173411bfdd	no	15
Warnings:					
Information:					
5	NPL Documents	Riemer_et_al_MolImmunol_2005_v42_p1121.pdf	638216 d424ac61b77553b7b01ed51dbcd7efcdce0246c5	no	4
Warnings:					
Information:					
6	NPL Documents	Roovers_et_al_CandImmunol_2007_v56_p303.pdf	554887 d4e57961d5148d4b45c2385791167b797d92691	no	15
Warnings:					
Information:					
7	NPL Documents	Rosenberg_AAPSJournal_2006_v8_pE501.pdf	167563 784fc51bec05e58a7d3b6ad6d68e4e938baa73d89	no	7
Warnings:					
Information:					
8	NPL Documents	Saerens_et_al_JMolBiol_2005_v352_p597.pdf	1147766 45d1124e1dd4117c4c4c2385791167b797d92691	no	11
Warnings:					
Information:					
9	NPL Documents	Scheurich_et_al_IntJCancer_1986_v38_p127.pdf	567969 d497cab70088b7674b79f4c38a267ed2bca9b49f	no	7
Warnings:					
Information:					
10	NPL Documents	Schlaeppli_et_al_JCancerResClinOncol_1999_v125_p336.pdf	675930 5621b647893861908003e3f73c4887ca3634665e	no	7
Warnings:					
Information:					

11	NPL Documents	Silacci_et_al_Proteomics_2005_v5_p2340.pdf	1498482 f72f3d2b4481dc518556895d1e191c291b74896c	no	11
Warnings:					
Information:					
12	NPL Documents	Smith_et_al_Bioconjugate_Chem_2001_v12_p750.pdf	743990 114238f9c2dd3e0815c20158822e4c75ce9d816c	no	8
Warnings:					
Information:					
13	NPL Documents	Stahl_et_al_PatholBiol_1997_v45_p66.pdf	1283074 a74c8f221a1f8aa1673cb6be08e11101203e7d16	no	11
Warnings:					
Information:					
14	NPL Documents	Stancovski_et_al_PNAS_1991_v88_p8691.pdf	1178830 e7baed79aed7415dc9f9b66f5c6c75b4d03e61f	no	5
Warnings:					
Information:					
15	NPL Documents	Terskikh_et_al_PNAS_1997_v94_p1663.pdf	860371 eeec3181e673038f6c2b8ccce288a2050e31650	no	6
Warnings:					
Information:					
16	NPL Documents	Tijink_et_al_MolCancerTher_2008_v7_p2288.pdf	1081552 0ca1f818e218b1c9469f86dc73d749c11495a5d7	no	10
Warnings:					
Information:					
17	NPL Documents	van_den_Beucken_JMolBiol_2001_v310_p591.pdf	605179 795f9212014a10e1d46f946196176fc379a5d82	no	12
Warnings:					
Information:					
18	NPL Documents	Van_Der_Linden_et_al_J_Immunol_Methods_2000_v240_p185.pdf	1059670 111b1908b9c2c2c884db78ca2f8ee7137018	no	11
Warnings:					
Information:					
19	NPL Documents	Vickers_DrugsAging_2002_v19_p487.pdf	1518765 0ad198f7c72095c2dbf3a83ed5e145f18f492ac	no	8
Warnings:					
Information:					

20	NPL Documents	VanderVaartetalVaccine2006v2 4p4130.pdf	705638 E2ae5d4d962a2e4dc1ed7d1dad3087c7 b6bc	no	8
Warnings:					
Information:					
21	NPL Documents	Waldmann_et_al_JClinInvest_1 972_v51_p2162.pdf	2508524 9f0078a7c1b094d13513678ba5c4ff6d4c0ff6 cb13	no	13
Warnings:					
Information:					
22	NPL Documents	Wesolowski_et_al_MedMicrobi olImmunol_2009_v198_p157. pdf	906381 0b27b2446c40946c427c9c3b760446c4c55 c805	no	18
Warnings:					
Information:					
23	NPL Documents	Winkler_et_al_J_Immunol_200 0_v165_p4505.pdf	3090929 0b0729604ee29c161334676318627926fae 3bfef	no	10
Warnings:					
Information:					
24	NPL Documents	Witte_et_al_Cancer_Metast_Re v_1998_v17_p155.pdf	689011 5d057a5a97900151e3e30150054edfecd35 662ba	no	7
Warnings:					
Information:					
25	NPL Documents	Zhu_et_al_InvestNewDrugs_19 99_v17_p195.pdf	1455093 3b2b9e13372d0151419aed36fe0813cddc 8c991	no	18
Warnings:					
Information:					
Total Files Size (in bytes):			26970928		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.